Skip to main
SER
SER logo

SER Stock Forecast & Price Target

SER Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Serina Therapeutics Inc, a clinical-stage biotechnology company, has shown potential for significant growth with its pipeline candidates advancing in high-value indications, particularly with SER-252. The company's POZ Platform delivery technology enhances the effectiveness of drug candidates and positions Serina favorably in the competitive landscape, creating opportunities for substantial market penetration. Additionally, the anticipated clinical success of SER-270 and its subsequent potential contributions to company valuations could offer long-term upside, further solidifying the positive outlook for Serina's stock.

Bears say

Serina Therapeutics reported a net loss of $0.64 per share, signaling significant financial difficulties within the company as it progresses through clinical development stages. The company faces numerous risks, including the potential inability to advance its lead product candidate, SER-252, into clinical trials and secure regulatory approval, along with challenges related to competition and market dynamics that could hinder commercial uptake. Additionally, projections for a deeper net loss of $2.01 per share in the full-year 2025 compared to an original estimate of $0.36 indicate worsening financial health and raise concerns about possible near- to medium-term dilution risks.

SER has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Serina Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Serina Therapeutics, Inc. (SER) Forecast

Analysts have given SER a Strong Buy based on their latest research and market trends.

According to 2 analysts, SER has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Serina Therapeutics, Inc. (SER)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.